On June 4, 2026, the U.S. Supreme Court issued its decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. The Court reversed the Federal Circuit, and held that Amarin’s complaint failed to plausibly allege that Hikma’s skinny label generic induced infringement of Amarin’s patents.
Author:
Matthew D. Zapadka, John D. Schneible Ph.D.